bioAffinity Technologies, Inc. (NASDAQ:BIAF) Short Interest Down 36.0% in July

bioAffinity Technologies, Inc. (NASDAQ:BIAF) was the target of a significant drop in short interest in July. As of July 15th, there was short interest totaling 522,561 shares, a drop of 36.0% from the June 30th total of 816,644 shares. Currently, 11.3% of the company’s stock are short sold. Based on an average daily volume of 589,484 shares, the short-interest ratio is presently 0.9 days.

Wall Street Analyst Weigh In

Several brokerages have commented on BIAF. Wall Street Zen raised shares of bioAffinity Technologies from a “sell” rating to a “hold” rating in a research report on Saturday, July 25th. Weiss Ratings restated a “sell (e+)” rating on shares of bioAffinity Technologies in a report on Monday, July 20th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of “Sell”.

bioAffinity Technologies Stock Performance

BIAF stock traded down $0.02 during trading hours on Friday, reaching $0.62. The stock had a trading volume of 79,539 shares, compared to its average volume of 3,923,887. The stock has a market capitalization of $2.96 million, a PE ratio of -0.05 and a beta of -1.11. The stock has a 50-day simple moving average of $1.06 and a 200 day simple moving average of $1.68. bioAffinity Technologies has a fifty-two week low of $0.56 and a fifty-two week high of $13.50. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.36 and a quick ratio of 1.34.

bioAffinity Technologies (NASDAQ:BIAF) last issued its earnings results on Friday, May 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.40) by $1.59. The company had revenue of $1.35 million for the quarter, compared to analysts’ expectations of $1.48 million. bioAffinity Technologies had a negative net margin of 280.53% and a negative return on equity of 285.75%.

Institutional Investors Weigh In On bioAffinity Technologies

A number of institutional investors have recently modified their holdings of the business. Geode Capital Management LLC bought a new position in shares of bioAffinity Technologies during the fourth quarter worth approximately $36,000. Scientech Research LLC acquired a new stake in shares of bioAffinity Technologies in the 3rd quarter valued at $49,000. Finally, J. Safra Sarasin Holding AG acquired a new stake in bioAffinity Technologies in the first quarter valued at about $164,000. Institutional investors own 1.64% of the company’s stock.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc (NASDAQ: BIAF) is a U.S.-based biotechnology company specializing in the development and commercialization of advanced in vitro diagnostic platforms for oncology. Leveraging proprietary bioaffinity and nanotechnology approaches, bioAffinity’s platforms are designed to isolate and analyze cancer-specific biomarkers from blood, tissue, and other biological samples with high sensitivity and specificity. The company’s core technologies aim to enable earlier detection of solid tumors, improved disease monitoring, and more personalized treatment strategies.

The company’s primary product pipeline includes assays targeting breast cancer and other solid tumor indications.